MDWD NASDAQ
MediWound Ltd.
1W: +3.7%
1M: -9.9%
3M: -12.5%
YTD: -31.9%
1Y: -31.9%
3Y: +54.9%
5Y: -46.0%
$12.55
+0.48 (+4.02%)
Weekly Expected Move ±5.7%
$11
$11
$12
$13
$13
Credit Risk of going bust: lower than 88% of companies Debt: 5.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), MediWound Ltd. would be worth roughly what it owes.
Total debt $9.5M against a stock market value of $162.0M.
Distance to default 12.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $932K (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' -9.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $9.5M against a stock market value of $162.0M.
Distance to default 12.80 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $932K (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' -9.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$162.0M
52W Range11.8-19.7
Volume117,412
Avg Volume88,851
Beta0.14
Dividend—
Analyst Ratings
Company Info
CEOOfer Gonen
Employees121
SectorHealthcare
IndustryBiotechnology
IPO Date2014-03-20
Websitemediwound.com
42 Hayarkon Street
Yavne, HM 8122745
IL
Yavne, HM 8122745
IL
972 7 797 14100
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Latest News
Brokerages Set MediWound Ltd. (NASDAQ:MDWD) Price Target at $33.00
MediWound (NASDAQ:MDWD) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why
MediWound (MDWD) Q2 2026 Earnings Call Transcript
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rubinstein Samuel | S-Sale | 525 | $12.72 | 2026-09-01 |
| Rubinstein Samuel | P-Purchase | 525 | $12.62 | 2026-09-01 |
| Hess Shmuel | S-Sale | 1,979 | $12.72 | 2026-08-27 |
| Hess Shmuel | S-Sale | 1,979 | $13.13 | 2026-08-27 |
| Hess Shmuel | M-Exempt | 11,000 | $8.13 | 2026-08-27 |